We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Deep Brain Stimulation Window May Matter for Parkinson’s Patients With GBA1 Variants

By HospiMedica International staff writers
Posted on 07 Oct 2026

Patients with GBA1 gene variants may develop significant physical symptoms earlier in life while also facing greater vulnerability to cognitive problems. More...

This combination can complicate decisions about when to consider deep brain stimulation. New findings now suggest that the timing of deep brain stimulation may influence memory and executive function outcomes in this genetically predisposed group.

The study was led by an international research team with involvement from Hackensack Meridian Neuroscience Institute (Hackensack, NJ, USA) at JFK University Medical Center and Hackensack Meridian School of Medicine. The work focused on deep brain stimulation, or DBS, a surgical therapy that functions like a pacemaker for the brain. DBS uses an implanted battery to deliver steady, mild electrical pulses to specific brain areas affected by Parkinson’s disease. These pulses help override abnormal brain signals that contribute to tremor, stiffness and involuntary movement.

Researchers analyzed data from 343 patients treated across 10 medical centers in the United States and Europe. They compared cognitive outcomes over time in patients with and without GBA1 mutations. The analysis also examined whether DBS was performed early or late in the course of Parkinson’s disease. The findings were published in Movement Disorders on October 1, 2026.

The results showed that cognitive risk in GBA1 mutation carriers was strongly linked to surgical timing. Patients with the mutation who received DBS later in their disease course had a significantly faster decline in cognitive abilities than those treated earlier. Among patients without the mutation, DBS timing did not affect cognitive outcomes. The data identified the first seven to eight years after Parkinson’s diagnosis as an important window for intervention.

The findings support earlier genetic testing as part of DBS evaluation in Parkinson’s disease. Identifying GBA1 status earlier could help patients and clinical teams weigh potential motor benefits against cognitive risks. The authors emphasized that a GBA1 variant should not automatically exclude patients from DBS. Instead, genetic information may help guide a more individualized treatment timeline.

“We may be approaching a turning point in how we use deep brain stimulation for Parkinson's disease. For decades, DBS decisions have largely been based on a patient's symptoms and clinical characteristics. Our research suggests that a patient's genetics—and importantly, the timing of surgery—may also matter. The future of DBS may not simply be deciding who should receive it, but identifying the right window to intervene for each individual patient. That moves us closer to truly personalized treatment for Parkinson's disease,” said Dr. Gian Pal, chief of neurology and director of the Movement Disorders Program at Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and associate professor of neurology at Hackensack Meridian School of Medicine.

Related Links
Hackensack Meridian Neuroscience Institute 


Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Patient Preoperative Skin Preparation
BD ChloraPrep
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Representative serial optical coherence tomography images of lesion-specific calcium modification. (Image Credit:: Annapoorna S. Kini et al. JACC: Cardiovascular Interventions, 2026. doi:10.1016/j.jcin.2026.10.001)

Dual-Technique Approach Improves Stent Expansion in Calcified Coronary Lesions

Calcified coronary nodules are hard, irregular calcium deposits that protrude into coronary arteries and can complicate percutaneous coronary intervention by preventing full stent expansion.... Read more

Patient Care

view channel
Image Credit: Adobe Stock

Video-Based Support Helps Older Adults Clarify Kidney Disease Treatment Preferences

Advanced chronic kidney disease (CKD) involves progressive loss of kidney function that can lead to kidney failure and difficult treatment decisions. For older adults, these decisions may include choosing... Read more

Point of Care

view channel
Image: Fluorescence image of water-acetone mixture condensation. (Photo courtesy of Jingcheng Ma/Interfacial Thermofluids Laboratory)

New Breath Condensate Testing Approach Enhances Reliability for COPD Monitoring

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that can increasingly impair breathing over time. Diagnosis and monitoring may be burdensome because patients often require... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.